Literature DB >> 7883738

The relationship between substance abuse and bipolar disorder.

K T Brady1, S C Sonne.   

Abstract

The significant prevalence of substance use disorders among patients with psychiatric illnesses has attracted increasing interest. One large epidemiologic study indicates that, of all Axis I disorders, bipolar disorder is the most likely to co-occur with alcohol or drug abuse. Evidence is emerging that shows that bipolar patients who also abuse drugs or alcohol have an earlier onset and worse course of illness compared with those who do not. They are more likely to experience irritable and dysphoric mood states, increased treatment resistance, and a greater need for hospitalization. Caution about diagnosing bipolar disorder in the presence of substance abuse is advised because of overlapping symptomatology. A rationale for the pharmacologic approach to treatment is explored. Data from several studies indicate that the presence of a substance use disorder may be a predictor of poor response to lithium. While it is possible that the anticonvulsants divalproex sodium and carbamazepine may be more useful in this population, a direct comparison of lithium with the anticonvulsants in a substance-abusing population of individuals with bipolar disorder has not yet been performed. Further investigation of diagnostic and treatment issues in this important population of patients with bipolar disorder is needed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7883738

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

1.  Use of potentially abusive psychotropic substances in psychiatric inpatients.

Authors:  J Modestin; C Nussbaumer; K Angst; P Scheidegger; D Hell
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 2.  Behavioral therapies for co-occurring substance use and mood disorders.

Authors:  Kathleen M Carroll
Journal:  Biol Psychiatry       Date:  2004-11-15       Impact factor: 13.382

3.  Adjunctive psychosocial intervention following Hospital discharge for Patients with bipolar disorder and comorbid substance use: A pilot randomized controlled trial.

Authors:  Susan J Wenze; Brandon A Gaudiano; Lauren M Weinstock; Katherine M Tezanos; Ivan W Miller
Journal:  Psychiatry Res       Date:  2015-06-15       Impact factor: 3.222

Review 4.  Psychiatric comorbidity in alcohol use disorders: results from the German S3 guidelines.

Authors:  U W Preuss; E Gouzoulis-Mayfrank; U Havemann-Reinecke; I Schäfer; M Beutel; E Hoch; K F Mann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-24       Impact factor: 5.270

5.  [Mental comorbidities of alcohol-related disorders].

Authors:  U W Preuss; E Gouzoulis-Mayfrank; U Havemann-Reinecke; I Schäfer; M Beutel; K F Mann; E Hoch
Journal:  Nervenarzt       Date:  2016-01       Impact factor: 1.214

6.  Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism.

Authors:  Jean-Michel Azorin; Charles L Bowden; Ricardo P Garay; Giulio Perugi; Eduard Vieta; Allan H Young
Journal:  Neuropsychiatr Dis Treat       Date:  2010-03-24       Impact factor: 2.570

7.  Impact of substance abuse comorbidity on psychopathology and pattern of remission in mania.

Authors:  P N Kumar; S S Raju
Journal:  Indian J Psychiatry       Date:  1998-10       Impact factor: 1.759

Review 8.  The bipolar patient with comorbid substance use disorder: recognition and management.

Authors:  Mark J Albanese; Ronald Pies
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Influence of postpartum onset on the course of mood disorders.

Authors:  Alessandro Serretti; Paolo Olgiati; Cristina Colombo
Journal:  BMC Psychiatry       Date:  2006-01-26       Impact factor: 3.630

Review 10.  Exclusion criteria and generalizability in bipolar disorder treatment trials.

Authors:  Jessie J Wong; Nev Jones; Christine Timko; Keith Humphreys
Journal:  Contemp Clin Trials Commun       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.